News
News
Company announcements, partnerships, research milestones, and media coverage.
HLB PANAGENE Launches AI-Powered Spatial Proteomics Platform with Arontier
Arontier Partners with Synthenta on Small Molecule Discovery
AI-Identified aPKC Drug Target Opens New Path for Type 2 Diabetes Treatment
Arontier’s AI mRNA Design Platform Achieves 10x Improvement in Expression
OrganoScience and Arontier Partner for AI-Assisted Preclinical Drug Testing
Arontier and KMEDI Hub Co-Host AD3 Platform Workshop
Arontier Joins National R&D Initiative for ADC Manufacturing Innovation
HLB Group Holds Inaugural Pitch Day for Portfolio Companies
Arontier Presents AphixANTIBODY Platform at PEGS Europe 2025
Arontier Showcases ‘Arontier PATH’ Digital Pathology AI at Industry Conference
Arontier Selected for Korea’s 2025 Super-Gap Deep-Tech Startup Program
Arontier Signs MOU with Celltrion Pharma for AI Drug Discovery
Arontier CEO Presents Comprehensive AI Drug Discovery Strategy at Precision Medicine Forum
PharmAbcine Partners with Arontier for AI Antibody Platform Development
Arontier Selected as Data Service Provider for Government Data Voucher Program
Arontier Spotlighted as HLB PANAGENE Wins Nobel Prize Recognition
HLB Group Makes 5 Billion KRW Strategic Investment in Arontier
Arontier Presents In Vivo Validation of ARC2-001 at AACR 2024
Arontier and Dongkook Pharmaceutical Sign AI Drug Development MOU
Arontier Selected to Lead MSIT National AI-Bio Data Project
Arontier Signs MOU and Secures Investment from HLB bioStep
Samjin Pharm and Arontier Collaborate on AI Immuno-Oncology Drug Discovery
Arontier Signs MOU with Gradient Bio for Organoid-Based Drug Screening
EyeGene and Arontier Partner for AI-Designed mRNA Vaccine Development
Arontier and KMEDI Hub Sign MOU for Patient-Customized NCE Development
Arontier Signs MOU with FutureMedicine for AI-Nucleoside Drug Discovery
Arontier Presents Anti-CAF Research ARC2-001 at AACR 2023
Arontier Develops AI-Powered Antibody Deimmunization Technology
Want to partner with us?
Arontier is actively seeking collaborative drug discovery programs and platform partnerships across all drug modalities.